Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies
Susanne M. Picker,
Volker Schneider,
Birgit S. Gathof,
Susanne M. Picker
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorVolker Schneider
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorBirgit S. Gathof
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorSusanne M. Picker,
Volker Schneider,
Birgit S. Gathof,
Susanne M. Picker
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorVolker Schneider
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorBirgit S. Gathof
From Transfusion Medicine, University of Cologne, Cologne, Germany.
Search for more papers by this authorSusanne M. Picker, Transfusion Medicine, University of Cologne, Kerpener Strasse 62, 50937 Cologne, Germany; e-mail: [email protected].
Abstract
BACKGROUND: Pathogen inactivation/reduction technology (PRT) may alter quality of stored platelet (PLT) concentrates (PCs). Therefore, PLT adhesion and aggregation should be studied before transfusion of PRT-treated PLTs.
STUDY DESIGN AND METHODS: A three-arm in vitro study on triple-dose apheresis PCs (n = 9) was conducted. Split single units were designated to PRT treatment with either a riboflavin (M)- or a psoralen (I)-based technique and compared to untreated controls (C). Samples were taken on Days 0, 1, 5, 7, and 8 to assess PLT function via a cone and plate(let) analyzer, flow cytometric P-selectin expression, and turbidometric aggregation response to thrombin receptor–activating peptide 6 (TRAP-6).
RESULTS: P-selectin expression increased and TRAP-6–inducible expression decreased steadily in all units until reaching a plateau on Day 5 of storage. PRT-treated units demonstrated significant (p ≤ 0.008) differences to C units due to a more pronounced upregulation in P-selectin expression after PRT treatment. The same was true for TRAP-6 after Day 5 of storage. C units were significantly superior over PRT-treated units (p ≤ 0.002), among which M yielded higher values than I (p ≤ 0.008). Although M demonstrated increased shear-induced PLT deposition that remained stable during storage (p = 0.082), surface coverage significantly declined in C (p = 0.047) and especially in I (p = 0.003), but differences between M, C, and I did not reach significance. All units exhibited a slight increase in aggregate size that remained comparable throughout storage (p ≥ 0.141).
CONCLUSIONS: Irrespective of storage-related changes in PLT activation and turbidometric aggregation response, riboflavin-based PRT seemed to benefit shear-induced PLT adhesion. The impact of this finding for PLT function and thrombogenesis in vivo must await clinical evaluation.
REFERENCES
- 1 Jilma-Stohlawetz P, Horvath M, Eichelberger B, Koren D, Jilma B, Panzer S. Platelet function under high-shear conditions from platelet concentrates. Transfusion 2008; 48: 129-35.
- 2 Murphy S, Gardner FH. Platelet storage at 22°C; metabolic, morphologic, and functional studies. J Clin Invest 1971; 50: 370-7.
- 3 Murphy S, Rebulla P, Bertolini F, Holme S, Monroff G, Snyder E, Stromberg R. In vitro assessment of the quality of stored platelet concentrates. The BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion. Transfus Med Rev 1994; 8: 29-36.
- 4 Snyder EL. Activation during preparation and storage of platelet concentrates. Transfusion 1992; 32: 500-2.
- 5 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
- 6 Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-3.
- 7 Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 1995; 9: 335-44.
- 8 Aarts PA, Van Den Broek SA, Prins GW, Kuiken GD, Sixma JJ, Heethaar RM. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis 1988; 8: 819-24.
- 9 Morrison A, Hornsey VS, Prowse CV, MacGregor IR. Use of the DiaMed Impact R to test platelet function in stored platelet concentrates. Vox Sang 2007; 93: 166-72.
- 10 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000; 99: 353-61.
- 11 German Medical Association and Paul-Ehrlich-Institute. Guidelines for the collection of blood and blood components and the usage of blood products (hemotherapy). Rev. ed. Cologne: Deutscher Ärzteverlag, 2005.
- 12 Council of Europe. Guide to the preparation, use and quality assurance of blood components. 13th ed. Strasbourg: Council of Europe Publishing, 2007.
- 13 Li J, Lockerbie O, De Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-6.
- 14 Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-9.
- 15 Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
- 16 Lin R, Alfonso R, Behrman B, Corten L, Damonte PB, Dikeman R, Dupuis K, Hei D, Lin CY, Londe HF, Metchette K, Phan T, Reames AA, Rheinschmidt M, Savoor A, Tessman J, Corash L. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infus Ther Transfus Med 1998; 25: 39-48.
- 17 Janetzko K, Klinger M, Mayaudon V., Lin L, Eichler H, Klüter H. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen-HCl and UVA light for pathogen inactivation. Infus Ther Transfus Med 2002; 29: 193-8.
- 18 Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 44: 320-9.
- 19 Panzer S, Eichelberger B, Koren D, Kaufmann K, Male C. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion 2007; 47: 103-6.
- 20 Shanwell A, Diedrich B, Falker C, Jansson B, Sandgren P, Sundkvist L, Svensson L, Vesterinen M, Gulliksson H. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion 2006; 46: 973-9.
- 21 Slichter SJ, Bolgiano D, Jones MK, Christoffel T, Corson J, Rose L, Foley J, Popovsky M, Baril LL, Corda T, Dincecco DM, Snyder EL. Viability and function of 8-day-stored apheresis platelets. Transfusion 2006; 46: 1763-9.
- 22 Vetlesen A, Mirlashari MR, Ezligini F, Kjeldsen-Kragh J. Evaluation of platelet activation during storage of platelet concentrates processed from buffycoats either manally or by the automatic OrbiSac system. Transfusion 2007; 47: 126-32.
- 23 Hagberg IA, Akkøk CA, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000; 40: 182-92.
- 24 Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 37: 12-7.
- 25 Rhenen van DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy-coats. Vox Sang 2000; 79: 206-14.
- 26 Metcalfe P, Williamson LM, Reutelingsperger CP, Swann I, Ouwehand WA, Goodall AH. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997; 98: 86-95.
- 27 Stohlawetz P, Horvath M, Pernerstorfer T, Nguyen H, Vondrovec B, Robisch A, Eichler HG, Spitzauer S, Jilma B. Effects of nitric oxide on platelet activation during plateletpheresis and in-vivo tracking of biotinylated platelets in humans. Transfusion 1999; 39: 506-14.
- 28 Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998; 92: 4446-52.
- 29 Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-91.
- 30 Peerschke EI, Silver RT, Weksler BB, Yin W, Bernhardt B, Varon D. Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. Am J Clin Pathol 2007; 127: 422-8.
- 31 Cauwenberghs S, Feijge MA, Theunissen E, Heemskerk JW, Van Pampus EC, Curvers J. Novel methodology for assessment of prophylactic platelet transfusion therapy by measring increased thrombus formation and thrombin generation. Br J Haematol 2007; 136: 480-90.
- 32 Matetzky S, Shankman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
- 33 Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N, Varon D. Testing the effect of GPIIb-IIIa antagonist in patients undergoing caroid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb Res 2001; 311-7.
- 34 Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, Rechavi G, Barzilai A, Martinowitz U, Savion N, Varon D. Cone and platelet analyzer (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101: 255-9.
- 35
Osende JI,
Fuster V,
Lev EI,
Shimbo D,
Rauch U,
Marmur JD,
Richard M,
Varon D,
Badimon JJ.
Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
Circulation
2007; 103: 1488-91.
10.1161/01.CIR.103.11.1488 Google Scholar
- 36 Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D, Pabinger I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007; 37: 814-9.
- 37 Lozano M, Galan A, Mazzara R, Corash L, Escolar G. Leukoreduced buffy-coat derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47: 666-71.
- 38 Gerrah R, Brill A, Tshori S, Lubetsky A, Merin G, Varon D. Using cone and plate(let) analyzer to predict bleeding in cardiac surgery. Asian Cardiovasc Thorac Ann 2006; 14: 310-5.
- 39 Van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, De Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy-coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
- 40 McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaze I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-41.
- 41 Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan AG. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46: 731-40.
- 42 Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, Sorensen H, Borregaard N, Flament J. Transfusion of 7-day old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006; 46: 424-33.
- 43 AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
- 44 Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG. Recovery and life span of 111indium-radiolabled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44: 1732-40.
- 45 Picker SM, Steisel A, Gathof BS. Effects of MIRASOL PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 4448: 1685-92.
- 46 Rognoni F, Viganò V, Colombo Pirola L. Influence of platelet anti-aggregants on mitochondrial respiration of platelets. Boll Soc Ital Cardiol 1977; 22: 2140-6.
- 47 Abou-Khalil S, Abou-Khalil WH, Yunis AA. Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria. Biochem Pharmacol 1986; 35: 1855-9.
- 48 Abou-Khalil WH, Lim LO, Yunis AA, Abou-Khalil S. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984; 33: 3893-8.
- 49 Kostelijk EH, Folman CC, Gouwerok CW, Kramer CM, Verhoeven AJ, De Korte D. Increase in glycocalicin levels in platelet concentrates stored in plasma or synthetic medium for 8 days: comparison with other platelet activation markers. Vox Sang 2000; 79: 21-6.
Citing Literature
